Silence Therapeutics plc
SLNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How SLN's past catalysts played out
SLN124
Polycythemia Vera
SLN360
Cardiovascular Diseases
Atu027 & gemcitabine in lead in safety period
Carcinoma, Pancreatic Ductal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SLN124 | Phase 2 | Polycythemia Vera | - | - |
SLN360 | Phase 2 | Cardiovascular Diseases | - | - |
Atu027 & gemcitabine in lead in safety period | Phase 2 | Carcinoma, Pancreatic Ductal | - | - |
Frequently asked questions
What is in Silence Therapeutics plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Silence Therapeutics plc's (SLN) pipeline across Phase 2. Its lead program is SLN124 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Silence Therapeutics plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Silence Therapeutics plc (SLN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SLN biotech catalysts?→
Add SLN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Silence Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.